Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation ...

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Amgen's market standing. Stay informed and make well-considered decisions with our ...

Matthew Popkin will serve as the next Ward 2 representative on the Longmont City Council. During a special meeting Tuesday, four members of the City Council – council members Shiquita Yarbrough ...

Now’s the time to stop and rethink Longmont development The problem: a lack of visionary thinking about solving Longmont’s housing problems and developers offering cookie-cutter solutions that ...

Tonight, the Longmont City Council will select a replacement for Council member Marcia Martin, concluding the process initiated by her resignation after seven years of honorable service. While ...

Between 3% and 5% of colorectal cancers exhibit the KRAS G12C mutation. Credit: SewCreamStudio/Shutterstock. Amgen’s LUMAKRAS (sotorasib) and Vectibix (panitumumab ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other high yield dividend stocks. Dow is one of the most well-known and influential stock market ...

The Food and Drug Administration has approved Amgen sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA approvals. Calquence, in combination with chemotherapy bendamustine and ...

The U.S. Food and Drug Administration (FDA) gave Amgen (NASDAQ:AMGN) approval to use its KRASG12C inhibitor Lumakras with Vectibix for treating advanced colorectal cancer. Warning! GuruFocus has ...